|Bid||0.00 x 900|
|Ask||92.88 x 800|
|Day's Range||92.23 - 92.99|
|52 Week Range||64.78 - 93.34|
|Beta (3Y Monthly)||0.54|
|PE Ratio (TTM)||17.60|
|Forward Dividend & Yield||2.83 (3.06%)|
|1y Target Est||99.50|
Conatus Pharmaceuticals Inc said on Monday it plans to explore options and implement a restructuring plan after its liver disease drug failed in a mid-stage trial. The drug was being developed to treat patients with nonalcoholic steatohepatitis (NASH), a fatty liver disease where fat accumulation and inflammation can lead to scarring, or fibrosis, that impairs liver function. Novartis AG in 2017 had exercised its option with Conatus to develop emricasan.
The upward trajectory of prescription drug prices in the U.S. has drawn the ire of lawmakers. Prices of drugs are staggeringly high in the U.S. when compared to other developed countries such as Japan and in Europe. House lawmakers are discussing a plan that could work to curb high drug prices.
Health-care reform is coming, UBS analysts say, and it could have severe consequences for health companies.
Novo Nordisk's (NVO) Esperoct gets EU approval for the treatment of adolescents (less-than or equal-to 12 years of age) and adults with haemophilia A.
A U.S. group that reviews the value of medicines issued a critical report on Novartis's new multiple sclerosis drug Mayzent, calling its $88,561 list price "far out of line" compared with its benefits for patients. The Boston-based Institute for Clinical and Economic Review (ICER), which has been reviewing Mayzent for months, recommended that Novartis lower the drug's price. Novartis disputed the findings.
A large pharmaceutical plant in Broomfield that for years produced generic drugs has been bought by a Boulder CBD company that’s looking to expand its ingredient-selling business to manufacturing mainstream products, like gummies, tablets and topicals. Mile High Labs purchased Novartis AG’s (NYSE: NVS) Sandoz plant in Broomfield, 2555 W. Midway Blvd., on Wednesday, June 19, for $18.8 million, company officials confirmed to Denver Business Journal.
Online pharmacy Valisure reported that it found a new cancer-causing impurity in some versions of widely prescribed blood pressure medicine valsartan, but U.S. regulators said on Tuesday that the amount in the drugs was well below levels deemed to be potentially harmful. Connecticut-based Valisure informed the U.S. Food and Drug Administration in a citizen petition https://www.regulations.gov/document?D=FDA-2019-P-2869-0001 last week that it had found through its own testing an impurity called dimethylformamide (DMF) in some batches of the drug. Valisure analyzed valsartan from multiple manufacturers including Novartis AG and several generic manufacturers.
Jazz Pharmaceuticals' (JAZZ) recently approved sleep drug, Sunosi, receives schedule IV designation under controlled substance list from the Drug Enforcement Agency.
Moody's Investors Service ("Moody's") has assigned a Baa2 rating to Alcon Inc.'s ("Alcon" or "the company") facilities. The loans are senior unsecured obligations of Alcon Inc..The proceeds from the above facilities were used alongside a $500 million 3-year senior unsecured term loan A, a $1.5 billion bridge-to-bond senior unsecured term loan and around $300 million equivalent local drawn lines to fund a $3,000 million payment to Novartis AG (A1 stable) and have a cash balance of approximately $500 million at closing of the spin-off from Novartis AG in April 2019.
Roche's (RHHBY) oncology portfolio gets a boost with the approval of Rozlytrek for neurotrophic tyrosine receptor kinase fusion-positive, advanced recurrent solid tumors.
J&J's (JNJ) Tremfya meets the primary endpoint in a late stage study that evaluated the efficacy and safety of the drug for treating patients with psoriatic arthritis.
Bluebird Bio plans to price a new gene therapy for people with an inherited blood disorder at almost $1.8m per patient, and will try to persuade European healthcare systems to shell out for it by promising to only seek full payment if it works. Healthcare systems will pay an initial instalment of €315,000 but will only pay more instalments if the treatment helps the patient avoid blood transfusions. The Boston-based biotech start-up’s drug is part of a class of new transformative therapies that need to be administered only once and apply to a small patient population.
Ligand's (LGND) subsidiary Vernalis enters research agreement with privately-held PhoreMost to design compounds targeting an undisclosed novel oncology target.
Elisa Mazen, who co-manages the $1.6 billion ClearBridge International Growth fund, isn’t afraid to take a broad definition of growth to find the best opportunities.
Stoke now hopes to raise $123 million when it launches on the Nasdaq market in the coming weeks, according to documents newly filed with the SEC. It originally had filed plans for an $86.25 million initial public offering last month. Stoke could be the fifth Massachusetts biotech to go public this year.
Dr. Reddy's (RDY) reports positive top-line results from the phase IIb study on PPC-06 (formerly referred to as XP23829) in patients with moderate to severe plaque psoriasis.
Moody's Investors Service has today assigned a B2 corporate family rating (CFR) and a B2-PD probability of default rating (PDR) to radiopharmaceutical products provider Curium Bidco S.a.r.l.. Concurrently, Moody's has assigned B2 ratings to the proposed senior secured first lien term loans B maturing in 2026, split into a 485 million equivalent US dollar-denominated tranche and a 250 million Euro-denominated tranche. Moody's has also assigned a B2 rating to the proposed pari passu ranking 120 million revolving credit facility (RCF) maturing in 2025. Senior secured first lien facilities shall be co-borrowed by Curium Bidco S.a.r.l., Curium Netherlands B.V. and Curium US Holdings LLC. The outlook is stable.